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CogStateOur previous study reported that a dried bonito broth known in Japan as ‘dashi’ improved or ameliorated mood
states, including fatigue, during the daily lives of human subjects. Histidine is an amino acid that is present in
dried bonito broth, and we sought to evaluate whether histidine would affect feelings of fatigue in humans.
We investigated the effects of histidine intake on the feeling of fatigue, mood states andmental task performance
by performing a placebo-controlled, double-blind crossover trial. Twenty subjects with high fatigue and sleep
disruption scores were asked to ingest histidine or a placebo every day for two weeks. The subjects' mood states
were evaluated using the Proﬁle of Mood States (POMS) scale and a visual analog scale (VAS) for eight feelings
(fatigue, depression, carelessness, drowsiness, clear thinking, motivation, attentiveness and concentration). We
also measured subjects' cognitive performance using the CogHealth test battery. The fatigue T-scores on the
POMS test decreased signiﬁcantly following histidine ingestion compared to placebo ingestion (p b 0.05). After
two weeks of histidine ingestion, the reaction time for the working memory task in the CogHealth test battery
was signiﬁcantly shorten compared to placebo ingestion. The VAS scores for clear thinking and for attentiveness
were increased signiﬁcantly following histidine ingestion compared to placebo ingestion (p b 0.05). These results
suggest that daily ingestion of histidinemay ameliorate feelings of fatigue, increase performance during working
memory tasks, and improve the clear thinking and attentiveness.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Fatigue is a common sensation that is caused by a variety of activities
associated with daily life, although fatigue is also associated with
psychiatric and other medical conditions [1]. Fatigue is associated with
reduced physical activity, drowsiness, and a desire to rest and is caused
by mental and physical workloads [2]. Mental fatigue is deﬁned as a
psychobiological state caused by a prolonged period of demanding
cognitive activity [3], and it is measured as a reduction in the ability to
perform mental tasks. Working on cognitively demanding tasks for a
considerable amount of time often leads to mental fatigue, which can& Technologies, Food Products
anagawa 210-8681, Japan.
sahara).
. This is an open access article underimpact task performance [4]. Several studies have reported that sleep
disruptions, which may induce mental fatigue [5,6], decrease cognitive
functioning and psychomotor vigilance task (PVT) performance [7,8].
Although mental fatigue is a very common phenomenon in modern,
everyday life, very little is known about the psychophysiological
mechanisms underlying mental fatigue [9]. Moreover, despite the
many studies on fatigue, it is remarkably difﬁcult to understand mental
fatigue and the cognitive processes underlying its behavioral manifesta-
tions [4].
In Japan, bonito (skipjack tuna; Katsuwonus pelamis) is among the
most commonly consumed ﬁsh, and dried bonito broth is used more
frequently than beef or chicken bouillon for soup stock [10,11]. Dried
bonito is called katsuobushi, and its broth is called dashi; both ingredi-
ents are commonly used in traditional Japanese meals [12]. Several
studies have reported improvements in or amelioration of mood states,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Baseline data for the study subjects.
Group A Group B p value All subjects
Mean + SD Mean + SD Mean + SD
Parameter
Number 10 10 20
Age 51.9 ± 4.8 51.0 ± 4.5 0.671 51.5 ± 4.6
Height (cm) 172.2 ± 6.3 171.8 ± 4.6 0.857 172.0 ± 5.4
Weight (kg) 77.2 ± 7.4 73.3 ± 11.9 0.388 75.3 ± 9.9
BMI 26.0 ± 2.2 24.9 ± 4.2 0.448 25.5 ± 3.3
POMS
Tension–anxiety 20.90 ± 6.31 17.80 ± 5.85 0.254 19.35 ± 6.13
Depression–dejection 30.50 ± 16.13 21.90 ± 7.71 0.271 26.20 ± 13.07
Anger–hostility 29.00 ± 11.25 19.90 ± 6.87 0.059 24.45 ± 10.21
Vigor 9.90 ± 4.48 7.50 ± 4.97 0.222 8.70 ± 4.77
Fatigue 20.50 ± 3.84 19.50 ± 4.14 0.616 20.00 ± 3.92
Confusion 18.10 ± 5.57 15.00 ± 5.16 0.224 16.55 ± 5.46
PSQI 8.50 ± 1.96 8.60 ± 2.95 0.930 8.55 ± 2.44
p value; comparisons between groups were made with unpaired Student's t-tests.
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following ingestion of dried bonito broth (DBB) [10,11,12,13,14]. In par-
ticular, ingestion of DBB has been shown to improve scores for the six
mood factors, including the feeling of fatigue and the total mood distur-
bance, on the Proﬁle of Mood States (POMS) questionnaire in young
women [11]. DBB ingestion also improved the scores for the feeling of
fatigue and for total mood disturbance among middle-aged subjects
with a high fatigue score, as shown by poorer mental task performance
(Uchida-Kraepelin psychodiagnostic test score) [10]. DBB contains
abundant quantities of histidine, as histidine makes up approximately
10% of its dry matter [15], and histidine is the precursor of histamine,
which functions as a neurotransmitter in the brain.
Neuronal histamine has been implicated in a variety of brain func-
tions. Central histaminergic neurons are located exclusively in the
tuberomammillary nucleus of the posterior hypothalamus, and they pro-
ject extensively throughout the brain [16,17]. Neural histamine acts as a
neurotransmitter through four types of histamine receptors. Histamine
H1 receptors moderate a variety of physiological functions, including
wakefulness, appetite, cognition and emotion [18]. Indeed, object recog-
nition and Barnes maze performance were found to be signiﬁcantly im-
paired in both H1 receptor knockout and H2 receptor knockout mice
[19]. The nucleus accumbens is the brain region that controlsmotivation,
and the striatum is the region that controls psychomotor function [18,20,
21]; stress alters the turnover of histamine in the brain, and acute stress
increases the levels of histamine and histamine-degrading enzymes in
the diencephalon, nucleus accumbens and striatum [22]. Furthermore,
chronic restraint stress has been shown to increase the levels of
histamine-degrading enzymes in the nucleus accumbens and striatum
in Fischer rats [23]. It is also known that chronic stress often results in de-
pression and chronic fatigue syndrome in humans [1,24,25], and both of
these conditions promote low motivation and body-dragging [1,24].
In humans, neural histamine modulates a variety of physiological
functions, such as wakefulness, learning and memory, and emotions
[18]. Depressed patients show decreased brain histamine H1 receptor
binding, and this decrease correlates with the severity of depression
symptoms [25]. A histamine H1 receptor blocker induces drowsiness
and decreases psychomotor performance [26]. Antihistamines prolong
the braking reaction time when subjects experience dual-task interfer-
ence while driving [27] and are known to increase tiredness and impair
cognitive functions [18,26,27].
Oral amino acids are absorbed into the blood from the small intes-
tine, and histidine has been reported to cross the blood–brain barrier
in mammals [28,29,30]. These ﬁndings suggest that ingesting histidine,
the precursor of histamine, may increase brain histamine levels and
reduce mental fatigue in humans.
Based on the results of these previous studies, we hypothesized that
histidine intake could ameliorate the feeling of fatigue and improvemen-
tal task performance in subjects with a feeling of fatigue or mental fa-
tigue. In the present study, we examined the effects of daily histidine
ingestion on the feeling of fatigue and on mental task performance
using a placebo-controlled, double-blind study of middle-aged subjects
who had high fatigue scores on the Japanese version of the POMS ques-
tionnaire [31] and high sleep disorder scores on the Pittsburgh sleep
quality index (PSQI) [32]. We evaluated subjects' feelings of fatigue
using the POMSquestionnaire andmeasured their performances ofmen-
tal tasks using simple card game tests called the CogHealth test battery.
We alsomeasured somemental states that could be accompanied by ac-
tivation of histaminergic neurons using the visual analog scale (VAS).
2. Materials and methods
2.1. Participants
The subjects included 20healthy adultmen (45 to 65 years old)with
high fatigue scores on the POMS questionnaire (over 16 points) and the
PSQI (over 5 points). A fatigue score greater than 16 points on the POMSquestionnaire indicates that the study subject had greater feelings of
fatigue than normal Japanese individuals, and a PSQI score greater
than 5 points indicates that the study subject sleeps poorly and fre-
quently experiences mental fatigue [5,6]. We excluded people with a
history of a chronic disease that is correlated with fatigue, smokers,
those who regularly consumed energy drinks, and those who regularly
consumed ﬁsh containing high concentrations of free histidine. No
study subject had sleep apnea. This study was approved by the Ethics
Review Committee of the Shinkokai C'est La Vie Shinbashi Clinic Medi-
cal Corporation. After the purpose, procedures and schedule of the
studywere explained, informed consent was obtained from all subjects,
in accordancewith theHelsinki Declaration. Twentymenwere enrolled
as study subjects and randomly divided into two groups, group A and
group B. The baseline data regarding age, physical characteristics,
mood factors, and sleep-state scores for the study subjects are shown
in Table 1.2.2. Test samples
The test samples were prepared as follows. A 1.65-g quantity of
L-histidine (Ajinomoto Co., Inc., Tokyo, Japan) was compressed into 5
hard gelatin capsules. To prepare the placebo, an equal volume of cellu-
lose (1.00 g) was compressed into 5 capsules. Both sample types were
packaged in identical aluminum pouches; the L-histidine samples and
the placebo samples were indistinguishable. The study subjects
ingested capsules containing either the test substance or the placebo
once daily, in the morning. We hypothesized that the optimal time for
treatment with histidine would be in the morning because histaminer-
gic neuronal activity shows a clear circadian rhythm, with high levels
during the active period [20].2.3. Study protocol
The subjects were randomly divided into two groups, groups A and
B. During the ﬁrst experimental period, subjects in group A ingested
one package of the test sample per day, in the morning after their
regular breakfasts, for 2 weeks, and those in group B ingested the place-
bo samples. A 2-week washout period was followed by a second exper-
imental period, in which the groups were reversed. To ensure that the
subjects actually took the capsules, we required them to record their in-
take daily and to submit their records with all empty capsule packages
and spares. The POMS test, the VAS and the cognitive assessment task
were administered before and after both experimental periods. All
assessments were performed at the same time on Saturday mornings
(from 7:30 to 11:30 AM). All measurements were performed in a
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mately 25 °C.2.4. Study endpoints
We deﬁned two primary endpoints for the study. One was a
decrease in the POMS fatigue T score. The other was an improvement
in the performance (reaction time and accuracy) of a cognitive function
task. The improvements in VAS scores described in Section 2.5were also
evaluated as we hypothesized that any change in themood state would
be affected by histaminergic neuronal activation.2.5. Assessments of mood states
Wemeasured the feeling of fatigue andmood states that are affected
by mental fatigue in the subjects using two assessment methods: the
POMS questionnaire and the VAS. The POMS—Japanese Version No.
850 (published by Kaneko Shobo Co., Ltd.) was used as a sensitive
measure of mood states. Sixty-ﬁve questions were presented on the
questionnaire, and the subjects responded to the questions on a ﬁve-
point scale to indicate how well the given adjective described their
mood over the past week (0, not at all; 1, a little; 2, moderately; 3,
quite a bit; and 4, extremely frequently). The questions covered six
mood factors (tension–anxiety, depression–dejection, anger–hostility,
vigor, fatigue, and confusion). High vigor scores reﬂected a good mood
or emotion, and low scores for the other factors also reﬂected a good
mood or emotion. T-scores were calculated from the ﬁve-point scores
using a T-score conversion table (Kaneko Shobo Co., Tokyo, Japan). A
T-score of 50 points is the average T-score for Japanese individuals. In
the present study, T-scores were used to determine subjects' mood
states. The total mood disturbance (TMD) was obtained by subtracting
the vigor score from the sum of the tension–anxiety, depression,
anger–hostility, fatigue and confusion scores. Using the POMS question-
naire allowed the comparisons between time points.
For the VAS, eight questions were asked to provide a measure of the
subject's condition and levels of fatigue, depression, carelessness,
drowsiness, clear thinking, motivation, attentiveness, and concentra-
tion, all of which are known to be affected by the activity of brain hista-
mine neurons. The VAS consisted of a 10-cm line drawn from one
extreme to the other (“not at all” to “most”), with subjects indicating
the point on the line that applied to them at that moment in time.
Both the POMS and the VAS allow comparisons to bemade between
time points.Table 2
Changes in POMS T-scores after histidine and placebo ingestion.
Mood Capsule 0 W 2 W
Mean ± SD Mean ± SD
Tension–anxiety Histidine 56.60 ± 9.77 53.85 ± 11.35
Placebo 51.95 ± 9.93 51.90 ± 9.77
Depression–dejection Histidine 60.80 ± 12.78 55.70 ± 12.30
Placebo 57.75 ± 12.48 56.50 ± 12.12
Anger–hostility Histidine 59.00 ± 12.51 53.85 ± 12.52
Placebo 54.55 ± 12.49 54.00 ± 14.02
Vigor Histidine 41.85 ± 7.46 43.20 ± 8.65
Placebo 42.45 ± 8.32 42.90 ± 8.50
Fatigue Histidine 62.00 ± 8.65 56.05 ± 7.58
Placebo 58.80 ± 10.90 57.75 ± 9.38
Confusion Histidine 60.75 ± 10.67 55.15 ± 9.62
Placebo 57.35 ± 10.32 55.65 ± 9.00
TMD Histidine 257.30 ± 46.30 231.40 ± 46.89
Placebo 237.95 ± 49.20 232.90 ± 47.96
Values are means ± SDs (n = 20).2.6. Cognitive assessments
Cognitive states were quantiﬁed using the CogHealth computerized
test battery (CogState Ltd., Melbourne, Australia), which is a validated
tool for measuring cognitive impairment induced by mental fatigue or
drowsiness in humans. This test was administered to all subjects before
and after both experimental periods, and the test required approxi-
mately 20 min to complete. The speciﬁc tasks employed, in the order
in which they were administered, were as follows: (a) simple reaction
time, a detection task that measured psychomotor function and infor-
mation progression; (b) choice reaction time, a card-identiﬁcation
task that measured visual attention; (c) one-back working memory, a
one-card learning task that was a continuous visual recognition leaning
task that measured visual learning and memory; (d) visual learning, a
delayed recall task that measured continuous retention and recall;
and (e) continuous performance, a divided attention task that mea-
sured the ability to maintain focused attention. For each task, a single
primary outcome measure was identiﬁed. Performance was measured
in terms of speed (i.e., reaction times, recorded in msec) or accuracy
(i.e., arcsine proportion correct).2.7. Statistical analysis
All values are expressed as means± standard deviations. Physiolog-
ical parameters, mood factors, and PSQI scores at baseline were com-
pared using unpaired Student's t-tests. POMS scores, VAS scores, and
cognition data were compared by ANOVAs, with capsule (placebo and
histidine), time period (periods before and after washout periods),
and carry-over effects (groups A and B) as within-subject factors.
SPSS Statistics version 20.0 software (SPSS Inc., Chicago, IL, USA) and
SAS System Software (version 9.3, SAS Institute, NC, USA) were used for
statistical analyses. The results were considered statistically signiﬁcant
at p b 0.05.
3. Results
3.1. Participants
The purpose of this study was to evaluate the effects of histidine
ingestion on the feeling of fatigue. No effect of trial order on participant
responses was observed in the fatigue scores on the POMS question-
naire (p N 0.05); thus, all participant responses were analyzed together.
In addition, no effect of trial order on physiological parameters or PSQI
scores was observed.
Table 1 shows the subjects' baselinemood state. Themean scores for
“tension and anxiety”, “depression and dejection”, “anger and hostility”,
“fatigue” and “confusion”were high-normal scores thatwerewithin the
normal Japanese range. The mean score for “vigor”was low-normal for
Japanese individuals.
3.2. Changes in POMS T-scores
The T-scores for the POMS questionnaire and the changes in POMS
scores are shown in Table 2 and Fig. 1, respectively. After 2 weeks of
histidine ingestion, fatigue scores were decreased compared to baseline
fatigue scores at week 0. Signiﬁcant effects of the capsule (placebo or
histidine) in the change in the level of fatigue were observed [F(1,
19) = 5.55, p b 0.05].
3.3. Changes in temporary moods (VAS)
The mean VAS scores for each of the eight temporary moods were
measured in the placebo and histidine treatment groups at the begin-
ning and end of the 2-week trial period; the results are shown in
Table 3. The mean changes from the baseline scores at the end of the
2-week trial are shown in Fig. 2.
No difference in the VAS scores for feelings of tiredness, depressive
mood, carelessness, drowsiness and concentration was observed
Fig. 1. A.: Changes in POMS T-scores from baseline following histidine (black) or placebo (white) ingestion (n=20) for tension–anxiety, depression–dejection, anger–hostility, vigor, fa-
tigue and confusion. Values are expressed asmeans± SDs. B: Changes in POMS T-scores frombaseline followinghistidine (black) or placebo (white) ingestion (n=20) for TMD. Table: To
analyze changes following treatment, POMS scores were evaluated by analysis of variance with capsule (histidine and placebo), time period (periods before and after washout periods),
and carry-over effects (groups A and B) as within-subject factors.
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the patterns of change between the histidine and placebo trials was
observed.
However, the VAS scores for clear thinking, motivation and atten-
tiveness increased after histidine ingestion compared to those at week
0. Signiﬁcant effects of the capsule (placebo or histidine) were observed
in the VAS scores for clear thinking [F(1, 19)=5.74, p b 0.05] and atten-
tiveness [F(1, 19) = 5.82, p b 0.05].
3.4. Cognitive assessment
The mean reaction times and accuracy rates for the placebo and
histidine treatment groups for each of the ﬁve CogHealth measures at
the start and end of the 2-week trial period are shown in Table 4. The
mean changes from the baseline reaction times at the end of the 2-
week trial are also shown in Fig. 3. Reaction times for all ﬁve measures
decreased from those at week 0 following 2 weeks of supplementationTable 3
Changes in eight temporarymoods according to VAS scores after the ingestion of histidine
or a placebo.
Question items Capsule 0 W 2 W
Mean ± SD Mean ± SD
Tiredness Histidine 6.43 ± 1.38 5.93 ± 1.39
Placebo 6.23 ± 1.66 5.41 ± 1.84
Depressiveness Histidine 4.87 ± 2.22 3.91 ± 2.17
Placebo 4.19 ± 2.32 3.91 ± 2.21
Careless Histidine 6.43 ± 1.37 5.67 ± 1.91
Placebo 5.85 ± 2.04 5.63 ± 2.12
Drowsiness Histidine 6.78 ± 2.10 5.85 ± 2.29
Placebo 6.09 ± 2.31 6.07 ± 2.11
Clear thinking Histidine 3.06 ± 1.60 4.20 ± 1.73
Placebo 4.14 ± 1.90 3.94 ± 1.82
Motivation Histidine 3.88 ± 1.46 5.14 ± 1.82
Placebo 4.54 ± 2.10 4.67 ± 1.38
Attentiveness Histidine 3.56 ± 1.27 4.56 ± 1.74
Placebo 4.49 ± 1.63 4.49 ± 1.95
Concentration Histidine 3.98 ± 1.38 4.85 ± 1.75
Placebo 4.39 ± 1.91 4.55 ± 1.91
Values are means ± SDs (n= 20).with histidine. Signiﬁcant effects of the capsule (placebo or histidine) on
reaction times in the visual learning task were observed [F(1, 19) =
6.49, p b 0.05].
4. Discussion
In this randomized, double-blind, placebo-controlled crossover
study, we have shown that in subjects with high fatigue scores and
sleep disruption scores, ingesting histidine for 2 weeks decreased
fatigue T-scores on the POMS questionnaire and decreased reaction
times in a visual learning task in a battery of cognitive tests. Histidine
ingestion also increased the sensation of thinking clearly and feelings
of attentiveness.
The POMS ﬁndings showed that fatigue scores after 2 weeks of
histidine ingestion were signiﬁcantly lower than those after ingestion
of the placebo. Previous research has shown that DBB intake decreases
negative mood factors and the TMD score of the POMS questionnaire
to a greater extent than placebo ingestion in female subjects [11]. This
previous study also reported a greater increase in vigor following DBB
ingestion than following placebo ingestion [11]. Kuroda et al. reported
that the fatigue scores and TMD scores of the POMS test after 4 weeks
of daily DBB ingestion were signiﬁcantly lower than those measured
prior to the ingestion period; after 2 weeks of DBB ingestion, the vigor
score for the DBB group was signiﬁcantly higher than that for the
placebo group [10]. These ﬁndings show that improvements following
histidine ingestion were similar to those following DBB ingestion,
indicating that the effects of DBB ingestion on mood factors may be ex-
plained by histidine, as DBB contains abundant quantities of histidine
[15]. In these previous studies, histidine content within DBB was
approximately 0.21 g [10] to 0.58 g [11]. In our current study, subjects
were treated with 1.65 g/day. However, in a similar study [10], DBB
ingestionwas shown to affectmood states to a degree similar to that ob-
served with the ingestion of histidine alone, even though DBB contains
less histidine than the amount of histidine thatwas administered alone.
This discrepancy may be explained by differences in subjects' ages or
genders, as it is known that POMS scores vary with age and gender
[33], with young women showing higher scores for negative affects
[34]. In this study, the subjects were all men over 45 years of age. In
Fig. 2. Changes in VAS scores from baseline following histidine (black) or placebo (white) ingestion (n= 20) for tiredness, depressiveness, carelessness, sleepiness, clarity of thought,
motivation, attentiveness, and concentration. Values are expressed as means ± SDs. Table: To analyze changes following treatment, VAS scores were evaluated by analysis of variance
with capsule (histidine and placebo), time period (periods before and after washout periods), and carry-over effects (groups A and B) as within-subject factors.
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markers and moods [11], the subjects were approximately 19 years
old and female. It is also possible that other nutrients in DBB may
have affected the results, as eating food [31] and drinking soup rich in
amino acids [35] are also known to affect mood.
The oral consumption of histidine has been shown to increase plas-
ma histidine concentrations [36]. Several reports have also shown that
histidine can be transported across the blood-brain barrier in rats [37]
and humans [30]. Histamine is synthesized from histidine through
oxidative decarboxylation by HDC in neurons and is known to have a
variety of physiological functions. Neuronal histamine acts on 4 types
of histamine receptors, known as the histamine H1, H2, H3 and H4 re-
ceptors [18], to modulate brain activities, including wakefulness, the
sleep–wake cycle, appetite control, learning and memory, stress, sei-
zures, and emotions [38,39,40]. Histamine H1 receptor binding hasTable 4
Changes in performance according to the CogHealth test battery after histidine or placebo
ingestion.
Parameter Capsule 0 W 2W
Mean ± SD Mean ± SD
Simple reaction
time
Reaction time (ms) Histidine 327.4 ± 48.2 308.5 ± 45.7
Placebo 310.1 ± 44.0 314.9 ± 56.1
Accuracy rate (%) Histidine 99.1 ± 1.9 99.7 ± 0.8
Placebo 99.1 ± 2.5 99.3 ± 1.5
Choice reaction
time
Reaction time (ms) Histidine 548.5 ± 77.3 532.9 ± 59.9
Placebo 540.5 ± 51.3 544.3 ± 65.0
Accuracy rate (%) Histidine 97.8 ± 3.1 97.4 ± 3.6
Placebo 95.3 ± 6.0 96.7 ± 5.5
One-back working
memory
Reaction time (ms) Histidine 730.4 ± 135.4 688.1 ± 104.8
Placebo 707.0 ± 118.0 708.2 ± 130.8
Accuracy rate (%) Histidine 94.1 ± 5.7 94.1 ± 5.7
Placebo 94.2 ± 6.2 93.7 ± 6.1
Visual leaning Reaction time (ms) Histidine 901.2 ± 191.7 877.5 ± 158.9
Placebo 886.9 ± 243.8 975.4 ± 176.2
Accuracy rate (%) Histidine 67.2 ± 8.6 70.6 ± 12.2
Placebo 66.8 ± 9.4 68.5 ± 12.4
Continuous
performance
Reaction time (ms) Histidine 611.3 ± 159.6 541.5 ± 95.6
Placebo 542.3 ± 101.5 541.9 ± 128.1
Accuracy rate (%) Histidine 96.1 ± 5.8 95.7 ± 4.1
Placebo 93.9 ± 6.5 95.8 ± 6.1
Values are means ± SDs (n= 20).been observed to be decreased in frontal and anterior cingulate cortex
areas in patients with depression compared with age-matched controls
[25]. Therefore, we hypothesize that orally administered histidine in-
creases brain histamine levels, which ameliorates feelings of fatigue
and improves mood and cognitive function via poorly understood
mechanisms.
The present CogHealth results showed that the reaction times for the
visual learning testmeasured after histidine ingestionwere signiﬁcantly
lower than those measured after placebo ingestion. The visual learning
test is able to assess working memory, which is one of the components
of cognitive function [41]. The use of working memory is associated
with activation of the prefrontal cortex [42], which has a role in cogni-
tive control [43]. Because histaminergic neurons project to the prefron-
tal cortex [44], a relationship between working memory and
histaminergic neurons has been discussed. It has been noted that
chewing behavior not only breaks down food into smaller pieces but
also affects cognition; speciﬁcally, gum chewing was shown to increase
accuracy in the n-back working memory task [45], which is associated
with histaminergic neuronal activation [46].
In Alzheimer's disease patients, the neuronal histamine content of
the brain has been found to be signiﬁcantly lower than that in healthy
controls [17]. The coordination of resources is the prime function of
working memory, with memory storage representing only one of
many potential demands on the system. Accordingly, Alzheimer's
patients show marked impairment in both memory and tracking tasks
when they are required to combine these two tasks [47]. Cognition is
believed to be especially important during fatigue because tiredness
affects productivity. Histamine H1 receptor knockout mice exhibit sig-
niﬁcantly less locomotor activity compared with wild-type animals
[48], as well as reduced aggressive behavior [49]. At moments when
high vigilance is required, such as when the lights are off or a change
in the environment occurs, mice lacking brain histamine due to a muta-
tion in histidine decarboxylase are unable to remain awake, which is a
prerequisite condition for responding to behavioral and cognitive
challenges [50]. In humans, depressed patients show decreased brain
H1R binding, H1R dysfunction (i.e., occupied by H1 receptor antago-
nist)-induced drowsiness, and impaired cognitive performance [25].
On-call doctors, whose occupations are associatedwith sleep restriction
and high mental fatigue, demonstrate impaired cognitive functioning
after on-call duty [7]. Also, PVT performance is reduced following
Fig. 3.Changes in CogHealth subtest results frombaseline followinghistidine (black) or placebo (white) ingestion (n=20) for the simple reaction time, the choice reaction time, one-back
workingmemory, visual learning, and continuous performance. Values are expressed asmeans± SDs. Table: To analyze changes following treatment, CogHealth scoreswere evaluated by
analysis of variance with capsule (histidine and placebo), time period (periods before and after washout periods), and carry-over effects (groups A and B) as within-subject factors.
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study because it can provide precise measurements of human cognitive
functions; these tests are capable of assessing not only cognitive impair-
ment but also fatigue, lack of sleep and drunkenness [51,52,53].
The VAS scores were also evaluated secondarily, as we hypothesized
that the index ofmood stateswould be affected by histaminergic neuro-
nal activation. Two weeks of histidine ingestion signiﬁcantly increased
the VAS scores for the ability to think clearly and for attentiveness.
The changes in VAS scores that were observed following histidine
ingestion were not observed after ingestion of the placebo. Moreover,
the score related to the ability to think clearly was signiﬁcantly higher
after histidine ingestion than after ingestion of the placebo, and these
results suggest that histidine had a remarkable effect on the ability to
think clearly and on attentiveness. These ﬁndings may be explained
by the neuronal function of histamine. In fact, depression is the most
prominent stress-related psychiatric disorder and encompasses distur-
bances in mood, sleep, appetite and physical potential, and the damp-
ened states of mind observed in depression are the opposite of the
states ofmind indicated by theVAS results for the subjectswho ingested
histidine in this study. Thus, the VAS results in this study indicate that
sustained histidine intake could potentially improve lucidity or
alertness via the activation of histaminergic neurons.
In this study, it is unclear whether histidine ingestion is directly
affecting fatigue or sleep quality since they greatly affect one another.
Future work will need to test how oral histidine affects human sleep
quality via actigraphy and/or polysomnography. Additionally, the
mechanisms by which the ability to think clearly and attentiveness
both increase remain to be determined.
The results of the present study showed that daily ingestion of
histidine improved mood states and cognitive abilities, includingwork-
ingmemory, inmiddle-agedmenwith feelings of fatigue. The improve-
ments observed following histidine ingestion were similar to those
observedwith the ingestion of DBB,which contains abundant quantities
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